Clinical trials: Childhood Neoplasm
Uveal Melanoma
Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
This study has two parts, dose escalation and dose expansion. For dose escalation, the primary objective is to estimate the maximum tolerated dose (MTD) of AEB071 in patients with uveal melanoma.
- Trial name
- NCT01430416
- Testing
- AEB071
- Where
- 5 sites in United States, France and 2 more
- Volunteers
- 153 people
- Sponsor
- Novartis Pharmaceuticals
Metastases, Cancer
ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer
This is a non-randomized, phase 1, study with the primary objective of determining the toxicities and establishing the maximum tolerated dose of ALIMTA when administered as a 10 minute infusion every 21 days with folic acid or…
- Trial name
- NCT00034463
- Testing
- ALIMTA, folic acid, multi-vitamins
- Where
- United States
- Sponsor
- Eli Lilly and Company
Endometrial Cancer
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
This is a multicenter, open-label, nonrandomized, Phase 2 umbrella study of retifanlimab in participants who have advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy.
- Trial name
- POD1UM-204 (NCT04463771)
- Testing
- retifanlimab, epacadostat, pemigatinib
- Where
- 65 sites in United States, Belgium and 5 more
- Volunteers
- 206 people
- Sponsor
- Incyte Corporation
Solid Tumor, Adult
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive…
- Trial name
- NCT04306900
- Testing
- TTX-030, budigalimab and mFOLFOX6, TTX-030, budigalimab and docetaxel, TTX-030 and mFOLFOX6
- Where
- 32 sites in United States, South Korea
- Volunteers
- 185 people
- Sponsor
- Trishula Therapeutics, Inc.
Metastatic Cancer, Epithelial Tumor
First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)
This study will evaluate the safety, tolerability and preliminary efficacy and also pharmacokinetics, immunogenicity and other pharmacodynamic effects to elucidate the mechanism of action of NG-350A, either alone or in…
- Trial name
- FORTITUDE (NCT03852511)
- Testing
- NG-350A
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- Akamis Bio
Metastatic Non-small Cell Lung Cancer
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients…
- Trial name
- LUNAR-2 (NCT06216301)
- Testing
- NovoTTF-200T, Pembrolizumab, Platinum based chemotherapy
- Where
- 104 sites in United States, Austria and 15 more
- Volunteers
- 734 people
- Sponsor
- NovoCure GmbH
Pain; Bone Neoplasms; Neoplasm Metastasis
A Study of Ibandronate (Bondronat) in Participants With Metastatic Bone Disease
This study will evaluate the efficacy, safety, and effect on quality of life of oral ibandronate (Bondronat) in participants with breast cancer and metastatic bone disease.
- Trial name
- NCT02564107
- Testing
- Ibandronate
- Where
- 8 sites in Bulgaria
- Volunteers
- 48 people
- Sponsor
- Hoffmann-La Roche
Pain, Neoplasm Metastasis
Efficacy and Tolerability of Zoledronic Acid With Radiotherapy in Pts With Advanced Osteolytic Bone Lesions
It is the aim of this multicentric clinical study to assess the efficacy and tolerability of zoledronic acid in combination with radiotherapy in patients with advanced osteolytic bone lesions in terms of the reduction of pain and…
- Conditions
- Pain, Neoplasm Metastasis, Cancer
- Trial name
- NCT00171964
- Testing
- Zoledronic acid in combination with therapy
- Where
- Germany
- Volunteers
- 75 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Melanoma
Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN therapeutic virus in combination with paclitaxel and carboplatin is effective and safe in the treatment of metastatic melanoma.
- Trial name
- NCT00984464
- Testing
- REOLYSIN, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Oncolytics Biotech
Pancreatic Adenocarcinoma
Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma
This is a Phase 1b/2 study of batiraxcept (AVB-S6-500) designed to evaluate the safety and efficacy of batiraxcept in combination with nab-paclitaxel and gemcitabine in subjects with locally advanced, recurrent, or metastatic…
- Trial name
- NCT04983407
- Testing
- batiraxcept, Nab paclitaxel, Gemcitabine
- Where
- 17 sites in United States
- Volunteers
- 34 people
- Sponsor
- Aravive, Inc.
Non-small Cell Lung Cancer
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that overexpress c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and…
- Trial name
- NCT03539536
- Testing
- Telisotuzumab vedotin
- Where
- 252 sites in United States, Australia and 24 more
- Volunteers
- 270 people
- Sponsor
- AbbVie
Intraocular Melanoma, Melanoma (Skin)
Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Intraocular Melanoma, Melanoma (Skin), Metastatic Cancer
- Trial name
- NCT00324727
- Testing
- melphalan, regional chemotherapy, systemic chemotherapy
- Where
- 12 sites in United States
- Volunteers
- 93 people
- Sponsor
- Delcath Systems Inc.
Basal Cell Carcinoma, Medulloblastoma
A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics, and determine the maximum tolerated dose of ZSP1602 in participants with basal cell carcinoma, adenocarcinoma of esophagogastric junction…
- Conditions
- Basal Cell Carcinoma, Medulloblastoma, Adenocarcinoma of Esophagogastric Junction, Small Cell Lung Cancer
- Trial name
- NCT03734913
- Testing
- ZSP1602
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Cancer, Neoplasm Metastasis
FoundationOne™ Test Registry Study
This study is a prospective, multicenter, observational study to characterize utilization patterns of the FoundationOne™ test by oncologists under conditions of routine clinical practice in the US.
- Conditions
- Cancer, Neoplasm Metastasis, Tumor
- Trial name
- FMI Registry (NCT01851213)
- Where
- United States
- Volunteers
- 510 people
- Sponsor
- Foundation Medicine
Breast Cancer, Metastatic
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
The Substudy Protocol ASPEN-09-03 is a Phase 2, single-arm, multicenter study evaluating the efficacy, safety, and tolerability of evorpacept in combination with trastuzumab and chemotherapy in participants with HER2-positive…
- Trial name
- ASPEN-09-03 (NCT07007559)
- Testing
- Evorpacept (ALX148), Trastuzumab, Paclitaxel
- Where
- 60 sites in United States, Canada and 6 more
- Volunteers
- 120 people
- Sponsor
- ALX Oncology Inc.
Breast Cancer (Locally Advanced or Metastatic)
A Clinical Trial Comparing the Efficacy and Safety of Different Doses of BL0175 Injection in Treating Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced or Metastatic Breast Cancer
The goal of this clinical trial is to compare the objective response rates (ORR) of different doses of BL0175 in patients with postmenopausal hormone receptor (HR)-positive, human epidermal growth factor receptor 2…
- Trial name
- NCT07658183
- Testing
- BL0175 Injection
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Best-Link Bioscience, LLC
Ovarian Cancer, Epithelial, Gastric Cancer
A Study of NX-1607 in Adults With Advanced Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
- Conditions
- Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT05107674
- Testing
- NX-1607, Paclitaxel
- Where
- 17 sites in United States, United Kingdom
- Volunteers
- 345 people
- Sponsor
- Nurix Therapeutics, Inc.
Advanced or Metastatic Solid Tumors, Malignancy
A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK114
A Phase 1 study to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary antitumor activity of AK114.
- Conditions
- Advanced or Metastatic Solid Tumors, Malignancy, Metastasis
- Trial name
- NCT05200273
- Testing
- AK114
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Akeso
Locally Advanced or Metastatic Medullary Thyroid Cancer, Medullary Thyroid Cancer
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
The purpose of this study is to evaluate the effect of patient outreach program on the proportion of time patients with MTC experience moderate or severe AEs during first 12 months of treatment with vandetanib
- Trial name
- NCT01298323
- Testing
- Patient outreach, Vandetanib
- Where
- 66 sites in Australia, Austria and 18 more
- Volunteers
- 205 people
- Sponsor
- Sanofi
Colorectal Neoplasm
Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer
This trial is being performed in two parts: Dose Escalation and Dose Expansion. The primary objective for the Dose Escalation part is to determine the safety and tolerability at different doses of DS-8273a administered in…
- Trial name
- NCT02991196
- Testing
- DS-8273a + nivolumab
- Where
- 4 sites in United States
- Volunteers
- 4 people
- Sponsor
- Daiichi Sankyo
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.